Patients with multiple relapse of acute promyelocytic leukemia: treatment history and response to RA + PB therapy
| Case no. . | No. of relapses . | Courses of RA . | Other agents† . | Response to RA + PB treatment . |
|---|---|---|---|---|
| 1 | 4 | 3 | CTA (4), ATO | NT |
| 2 | 2 | 2 | CTA (2), ATO | NT |
| 3 | 2 | 3 | CTA (5), ATO | No |
| 4 | 3 | 4 | CTA (3), ATO | No |
| 5 | 2 | 2 | CTA (3), ATO, Ab | NT |
| 6 | 3 | 3 | CTA (8), BMT, ATO | Yes |
| 7 | 4 | 3 | CTA (5), BMT, ATO, PB | No |
| 8 | 2 | 3 | CTA (3), Ab, ATO, PB | No |
| Case no. . | No. of relapses . | Courses of RA . | Other agents† . | Response to RA + PB treatment . |
|---|---|---|---|---|
| 1 | 4 | 3 | CTA (4), ATO | NT |
| 2 | 2 | 2 | CTA (2), ATO | NT |
| 3 | 2 | 3 | CTA (5), ATO | No |
| 4 | 3 | 4 | CTA (3), ATO | No |
| 5 | 2 | 2 | CTA (3), ATO, Ab | NT |
| 6 | 3 | 3 | CTA (8), BMT, ATO | Yes |
| 7 | 4 | 3 | CTA (5), BMT, ATO, PB | No |
| 8 | 2 | 3 | CTA (3), Ab, ATO, PB | No |
Treatment history before the detection of PML-RARα mutations.
RA indicates all-trans retinoic acid; PB, sodium phenylbutyrate; CTA, chemotherapeutic agent; ATO, arsenic trioxide; NT, not treated; Ab, HUM-195 antibody; BMT, allogeneic bone marrow transplant.
Numbers in parentheses indicate number of different, previously used chemotherapeutic agents.